Here is the bit, from the press release — if you miss him tomorrow, Friday is also an option, I gather:
…Cameron Durrant, MD, chairman and CEO, will speak at the Pharmaceutical Strategy Conference in New York City September 28-30, 2016. Dr. Durrant will discuss how innovative paradigms, such as the company’s Responsible Pricing Model, can make a transformative impact on two critical issues facing the industry: reputation and pricing.
“The Responsible Pricing Model is a leading commitment to operate in a new way, embedding affordability, transparency and reasonable return into our pricing as we execute our strategy to bring needed medicines to patients,” said Dr. Durrant. “We are pleased to be part of the Pharmaceutical Strategy Conference to connect with like-minded stakeholders and lead real progress for our industry.”
Details of the discussion panels follow:
Title: Industry Image Panel: Confronting Pharma’s Reputation Problem
Date: Thursday, September 29, 2016, 2:00 p.m. EDT
Participants: Dr. Cameron Durrant, KaloBios Pharmaceuticals; Dr. Benjamin Cowen, Milestone Pharmaceuticals; Lucy Abreu, Otsuka Pharmaceutical Companies; Gautam Gupta, Pfizer
Title: Reimbursement / Market Access Focus Panel: The Road To Value-Based Drug Pricing
Date: Friday, September 30, 2016, 9:15 a.m. EDT
Participants: Dr. Edmund Pezalla, Aetna; David Gilman, Huron Consulting; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Nathan Dowden, Rubius Therapeutics; Richard Ascroft, Takeda Pharmaceuticals….
Now you know — but as my commenters have been correctly pointing out — this (even taken along with all the new company’s other new initiatives) may well not be enough, to sustain new KaloBios, longer term.